NCT06307457View on ClinicalTrials.gov

A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

CompletedOBSERVATIONAL

Enrollment

604

Participants

Timeline

Start Date

March 6, 2024

Primary Completion Date

April 19, 2024

Study Completion Date

April 19, 2024

Conditions

Breast Cancer

Interventions

DRUG

Palbociclib in combination with AI

Patients with HR+/HER2- locally advanced or metastatic breast cancer treated with palbociclib in combination with AI as first-line treatment, in Denmark.

Trial Locations (1)

2100

Copenhagen University Hospital, Rigshospitalet, Copenhagen